A Capital Markets Outlook for 2025: 2024, A Year in Review
The Optimism of Bispecific Antibodies
Dynamics in Healthcare Focused Markets
From NASH to MASH: Current Market Dynamics in Hepatology
Key Considerations for a US IPO Process
Drug Development in Obesity
The Current Dynamics in Capital Markets
Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
The Most Notable Product Approvals of 2023
Monthly Roundup of News from Healthcare Development
The Current and Future Landscape of Healthcare IPO Markets
The Heart of the Matter: Behind the Shifting Interest in Cardiovascular Disease - A conversation on the rising trends in the cardiology space
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
Investing and Development in Health Tech & Digital Medicine
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
Preparing BioPharma and Medtech Companies for Public Listing Back Bay Life Science Advisors and Nasdaq Nordic
The Promising Field of Targeted Protein Degraders (TPDs)
Developer Questions on Pricing and Market Access
Living Medicines – Current and Future Uses of Car T Cells
The Evolving Regulatory Framework for Novel Medicines in the EU
The Commercial Potential of Optogenetic Therapies
The Latest on Antibiotic Development—with Antabio
Best Practices for Successful Sell-Side Licensing, Partnering and M&A
Cell and Gene Therapy Investment Trends
MedTech Investing with Paul LaViolette, SV Health Investors and Jonathan P. Gertler, BioVentures MedTech Funds
Surging Investment in Remote Patient Monitoring
New Drug Pricing and Market Access
The Question of Investment in Antimicrobials
Life Science SPACs, A Forward Look at this Evolving Asset Class
The Next Innovations in Gene Therapies: What’s to Come as The Industry Moves Forward
